The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis
<p>Abstract</p> <p>Objectives</p> <p>Dasatinib 100 mg daily and nilotinib 600/800 mg daily have been compared to imatinib as first line treatments for CML in two recent randomised studies. However, no head to head evidence exists of the relative efficacy of dasatinib an...
Main Authors: | Mealing Stuart, Barcena Leticia, Hawkins Neil, Clark James, Eaton Victoria, Hirji Ishan, Davis Catherine |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2013-02-01
|
Series: | Experimental Hematology & Oncology |
Subjects: | |
Online Access: | http://www.ehoonline.org/content/2/1/5 |
Similar Items
-
Resistant Bilateral Chylous Effusion as a Late Adverse Effect of Dasatinib Treatment in Chronic Myeloid Leukaemia
by: Emine Zengin, et al.
Published: (2019-08-01) -
Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
by: Chao‐Chin Hsu, et al.
Published: (2021-06-01) -
Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
by: Emilio Usala
Published: (2015-10-01) -
Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01) -
Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)